Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 2
Abstract
Sarcosine, a natural amino acid found in muscles and other body tissues, is an endogenous glycine transporter type 1 inhibitor that increases the glycine concentration, resulting in an indirect potentiation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Sarcosine, similar to other NMDA receptor-activating agents, is an effective adjuvant in the treatment of schizophrenia. It is widely accepted that increased glutamatergic neurotransmission is involved in the initiation and propagation of seizures. Because sarcosine facilitates NMDA receptor function, it may affect the seizure threshold. Therefore, we examined the effects of sarcosine on the seizure threshold in two different mouse seizure models: the timed intravenous (iv) pentylenetetrazole (PTZ) infusion test and the maximal electroshock seizure threshold test. In the iv PTZ test, sarcosine did not exert a significant effect on the seizure threshold at any of the doses tested (100, 200, 400 and 800 mg/kg, ip). However, at doses of 400 and 800 mg/kg, sarcosine significantly raised the threshold for electroconvulsions (p < 0.01). The present findings indicate that sarcosine did not lower the seizure threshold. Conversely, sarcosine showed weak anticonvulsant properties by increasing the threshold current for the induction of tonic seizures. Therefore, sarcosine may be considered as a safe adjuvant treatment for schizophrenia without proconvulsant risk. In addition, the compound may serve as an interesting addition to epilepsy treatment.
Authors and Affiliations
Katarzyna Socała, Dorota Nieoczym, Chris Rundfeldt, Piotr Wlaź
Keywords
Related Articles
- EP ID EP102454
- DOI -
- Views 85
- Downloads 0
Hypertriglyceridemia but not hypercholesterolemia induces endothelial dysfunction in the rat.
In humans, hypercholesterolemia and hypertriglyceridemia induce endothelial dysfunction and therefore lead to atherosclerosis. In contrast, rats are resistant to atherosclerosis. Here we analyze whether rats respond to h...
Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Combination with suitable pharmacological agents can improve the antiobesity and antidiabetic actions of glucagon like peptide-1 (GLP-1) based therapies. GLP-1 agonist exendin-4 may have insulin-independent effects on am...
Treatment of dyslipidemia in patients with diabetes mellitus.
The article reviews the key aspects of pathophysiology of diabetic dyslipidemia, its treatment and associated risk of cardiovascular complications. It examines the difference in lipidmetabolism between type 1 and type 2...
Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
The endocannabinoid system is a crucial player in the inflammatory processes underlying atherosclerosis. Recently, basic research studies and animal models have strongly supported the role of the endocannabinoid system n...
Urocortin: a protective peptide that targets both the myocardium and vasculature.
The urocortins are a family of endogenously produced peptide hormones that show great promise as potential drugs for the treatment of heart disease. They can increase contractility and cardiac output without causing chan...